Developing new economic models to incentivise antibiotic discovery and development activities while safeguarding the efficacy of antibiotics by researching and advocating their appropriate use.
DRIVE-AB Partner Laxminarayan Urges UN to Set Global Targets for AMR
DRIVE-AB Work Package 1C co-leader Ramanan Laxminarayan has co-authored an article ahead of the...
DRIVE-AB Partners Help Lead on New International Public-Private Partnership CARB-X to Fund Antibiotic Preclinical R&D
DRIVE-AB welcomes today's announcement of the establishment of The Combating Antibiotic Resistant Bacteria Biopharmaceutical...
DRIVE-AB Metrics & Indicators of Responsible Antibiotic Use Included in ECDC’s Draft EU Guidelines of Human Antibiotic Use
EMA Recommends Countries Reduce Colistin Use in Animals
The European Medicines Agency (EMA) has recommended that colistin-containing medicines should only be used...
Prof Otto Cars Interviewed About “Post-Antibiotic Era”
DRIVE-AB Work Package 2 partner Prof Otto Cars, Professor of Infectious Diseases at Uppsala University, was interviewed...